Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Timing matters: how mechanism-guided sequencing shapes the efficacy of radiotherapy-immunotherapy combinations : A systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
   Review
2. Increasing the Response of Mismatch Repair Proficient Rectal Cancer to Immunotherapy with Particle Radiation and DNA Damage Response Inhibitors-Preclinical Evidence.Cancers · 2026
   Review
3. Smart nanodelivery systems targeting tumor-associated macrophage reprogramming to potentiate cancer immunotherapy: pharmacological mechanisms, delivery strategies and translational perspectives.Frontiers in pharmacology · 2026
   Review
4. Endoscopic Immuno-Oncology: A New Frontier in Treatment of Pancreatic Cancer.Cancers · 2025
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as